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Abstract: Pompe disease is an autosomal-recessive lysosomal storage disorder characterized by
progressive myopathy with proximal muscle weakness, respiratory muscle dysfunction, and
cardiomyopathy (in infants only). In patients with juvenile or adult disease onset, respiratory muscle
weakness may decline more rapidly than overall neurological disability. Sleep-disordered breathing,
daytime hypercapnia, and the need for nocturnal ventilation eventually evolve in most patients.
Additionally, respiratory muscle weakness leads to decreased cough and impaired airway clearance,
increasing the risk of acute respiratory illness. Progressive respiratory muscle weakness is a major
cause of morbidity and mortality in late-onset Pompe disease even if enzyme replacement therapy
has been established. Practical knowledge of how to detect, monitor and manage respiratory muscle
involvement is crucial for optimal patient care. A multidisciplinary approach combining the expertise
of neurologists, pulmonologists, and intensive care specialists is needed. Based on the authors’ own
experience in over 200 patients, this article conveys expert recommendations for the diagnosis and
management of respiratory muscle weakness and its sequelae in late-onset Pompe disease.
Keywords: neuromuscular disorders; Pompe disease; respiratory muscle weakness; mechanical
ventilation; cough assistance
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1. Introduction
Empirical data on the management of respiratory muscle weakness in adults with Pompe disease
are scarce. Clinical recommendations for the care of patients with Pompe disease do not specifically
focus on respiratory issues and standard practice is largely based on guidelines covering chronic
respiratory failure in neuromuscular disease (NMD) in general [1–4]. A recent, more disease-specific
publication provides only limited coverage of practical aspects such as cough assistance, respiratory
muscle training, and ventilation techniques [5]. Lack of treatment guidelines has led to the adoption of
heterogeneous, often local standards of practice. The low prevalence of Pompe disease makes it difficult
to establish a national or international consensus. In order to create comprehensive recommendations
for diagnosis and management of respiratory muscle weakness, the Pompe Disease Respiratory
Care Working Group was formed in 2013, bringing together experts from various clinical disciplines.
The following recommendations provide practical, technical, and, wherever possible, disease-specific
guidance for physicians who care for patients with late-onset Pompe disease (LOPD).
2. Background
Pompe disease is an autosomal-recessive lysosomal storage disorder caused by α-1,4-glucosidase
(GAA) enzyme deficiency. Prevalence ranges between 1:40,000 and 1:100,000 [6]. GAA dysfunction
results in accumulation of glycogen in skeletal and smooth muscle cells, hepatocytes, endothelial cells,
and central nervous system neurons [7]. GAA activity below 1% is associated with early-infantile
disease onset, cardiomyopathy, cardiorespiratory failure, and early death if enzyme replacement
therapy (ERT) is not initiated [8]. Partial reduction of GAA enzyme activity is associated with
late-childhood, juvenile, or adult disease onset, which is mainly characterized by progressive
weakness of the limb girdle and axial muscles. In this article, the term “late-onset Pompe disease”
(LOPD) comprises virtually all disease subtypes other than early-infantile. In LOPD, respiratory
muscle dysfunction may precede limb girdle weakness, and ventilatory support is indicated prior to
wheelchair dependence in about one-third of patients [9]. Affected respiratory muscles comprise the
diaphragm in particular, but also the upper airway, and intercostal and abdominal muscles in advanced
disease [10–12]. Recent evidence shows that diaphragmatic dysfunction cannot only be attributed to
myopathic changes but also to accumulation of glycogen in cervical anterior horn cells and alterations
of both phrenic nerve fibers and neuromuscular junctions, respectively [13,14]. Thus, therapeutic effects
of ERT on diaphragmatic function may be limited since partial clearance of glycogen from myocytes
may be counterbalanced by persisting neuronal pathology. However, long-term ERT has been shown to
slightly improve forced vital capacity in patients with LOPD [15,16]. In untreated patients with LOPD
chronic respiratory failure slowly develops in more than 70% with a mean annual decline of the forced
vital capacity (FVC) of about 1.5% [17]. However, disease progression and diaphragmatic involvement
both are highly variable in LOPD patients with and without ERT making it obligatory to assess and
monitor respiratory muscle strength on an individual basis. Since impairment of respiratory muscle
function is still ongoing in one third of adults on ERT [18] anticipatory management strategies aim to
improve inspiratory muscle function and to early identify the need for ventilatory support. Work-up
of clinically apparent sleep disturbances is crucial since symptoms of sleep-disordered breathing (SDB)
may indicate respiratory muscle weakness [19]. In addition, impairment of cough and airway clearance
is a common finding in patients with respiratory muscle dysfunction since both inspiratory capacity
and expiratory force are reduced.
3. Assessment of Respiratory Muscle Function
3.1. Clinical Presentation
Daytime symptoms suggestive of respiratory muscle weakness include dyspnea on exertion
or rest, dyspnea on immersion in water, and reduced physical capacity. Sleep-related symptoms
include orthopnea, sleep disruption, morning headache, daytime hypersomnolence, and fatigue.
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Alveolar hypoventilation is more likely to occur in the supine position and during rapid eye movement
(REM) sleep when muscle tone is physiologically decreased. Impaired cough predisposes patients to
deep aspiration, mucus obstruction, and pulmonary infections. Reccurent respiratory infections or
prolonged recovery from such illnesses may reflect respiratory muscle weakness even before dyspnea
or sleep-disordered symptoms become apparent. Diaphragmatic dysfunction is usually accompanied
by weakness of the axial musculature and proximal limb muscles leading to hyperlordotic posture and
Trendelenburg’s gait.
3.2. Screening Questionnaires
Disease-specific screening questionnaires for symptoms of respiratory muscle weakness do not
exist. Validated screening questionnaires including the Medical Research Council (MRC) Breathlessness
Scale [20] the Baseline and Transition Dyspnea Index [21] or the Modified Borg Scale [22] can be used to
evaluate dyspnea. However, none of these instruments has been validated for neuromuscular disease
or LOPD in particular. Only the Sleep-Disordered Breathing in Neuromuscular Disease Questionnaire
(SiNQ-5) [23] has been specifically designed for patients with NMD but has not widely been used.
3.3. Clinical Examination
Respiratory rate, speech, and activation of auxiliary respiratory muscles should be assessed in the
upright and supine position. In the latter, paradoxical breathing may be present reflecting advanced
diaphragmatic weakness. With disease progression, patients may be unable to sustain the supine
position without ventilatory support, and long-standing hypercapnia may cause bilateral ankle edema
or clinical signs of cor pulmonale, although this is rare [24].
3.4. Measurement of Respiratory Muscle Function
3.4.1. Pulmonary Function Tests (PFTs)
Normal values for PFTs have been published [25,26]. PFTs usually show restriction with a decrease
in vital capacity (VC) and total lung capacity (TLC). VC is defined as the maximal volume a patient
can exhale or inhale, respectively. Notably, VC does not directly reflect respiratory muscle strength but
depends on inspiratory and expiratory muscle function alongside with the structural features of the
chest wall and the lungs. Various methods of VC testing have been described including VC, forced
and slow VC (all expiratory) or inspiratory VC (IVC). However, these maneuvers all assess the same
parameter in any given individual. VC may differ from FVC only in patients with chronic obstructive
lung disease, and SVC (slow vital capacity) may be superior to FVC if there is a risk of air leakage
due to impaired lip closure or insufficient sealing of the nasopharynx by the velum, respectively.
If respiratory muscle weakness is just emerging, an isolated decrease of VC can be observed while
TLC is still normal [27]. VC should be evaluated in both the upright and supine positions, and a >20%
drop indicates significant diaphragmatic weakness [28]. Decreased IVC is predictive of either SDB
(<60%), or nocturnal hypoventilation (<40%) [28,29] and an IVC < 25% has been shown to be associated
with diurnal respiratory failure in NMD [30]. Expiratory muscle weakness may significantly alter the
upright VC and the expected positional drop of the VC.
3.4.2. Peak Cough Flow (PCF)
PCF can be obtained using a hand-held device. Healthy adults show PCF > 400 L/min.
A PCF < 160 L/min reflects inadequate airway clearance. Values between 160 and 270 L/min predict
susceptibility to respiratory tract infections [31]. PCF should be routinely measured if PCF was
<270 L/min once (or <160 L/min during acute exacerbation) and if impaired cough is clinically apparent.
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3.4.3. Manometry
Maximal inspiratory pressure (MIP), sniff nasal inspiratory pressure (SNIP), and maximal
expiratory pressure (MEP) are volitional measures of respiratory muscle strength. Changes of MIP
and MEP are often detectable before VC and TLC decline. MIP and MEP testing should be performed
according to accepted standards [32]. Reference values and equations have been published [33,34].
All tests should be repeated at least three times. MIP and SNIP are considered complementary rather
than interchangeable, and when both techniques are applied, the highest value measured should be
recorded [35]. The technique that is performed best by a patient should be used for follow-up.
3.4.4. Non-Volitional Tests
Non-volitional measures of diaphragmatic strength include transdiaphragmatic twitch pressure
(Pdi) and twitch mouth pressure (Pmo) after magnetic phrenic nerve stimulation [36]. Since Pdi
is highly correlated to VC, MIP, and MEP in adults with Pompe disease, invasive assessment of
respiratory muscle strength is not advisable in routine clinical settings. Phrenic nerve conduction
studies and needle electromyogram of the diaphragm may yield further information on diaphragmatic
function but have not been evaluated in patients with LOPD. Imaging techniques that help assess
diaphragmatic function include transmission radiography, ultrasound and magnetic resonance (MR)
tomography. Thoracic radiography is widely available but has limited sensitivity and does not allow
for quantification of RMW (respiratory muscle weakness) [32]. Ultrasound can reveal both impaired
excursions and reduced thickness of the diaphragm [37]. MR imaging may potentially be useful to
detect altered diaphragm kinetics in neuromuscular disease including LOPD [38], however, normative
values and clinical validation are still lacking, thus preventing its use in clinical routine to date.
In summary, various complementary methods of respiratory muscle assessment are available
and should be utilized to facilitate the diagnosis of either SDB or daytime respiratory failure in
ventilator-free patients. FVC, MIP, and MEP have been shown predict the need for mechanical
ventilation in LOPD [39] and should be preferred for primary assessment. In addition, the above
measures allow for monitoring of disease progression and proper timing of follow-up visits in both
ventilated and non-ventilated patients (Table 1). For practical reasons, measurement of FVC or IVC in
the upright and supine position is most likely to be readily available, and further methods may be
provided only by specialized centers.
Table 1. Practical recommendations for inspiratory and expiratory muscle testing in LOPD. LLN, lower
limit of normal; MEP, maximal expiratory pressure; MIP, maximal inspiratory pressure; PCF, peak cough
flow; SNIP, sniff nasal inspiratory pressure; TLC, total lung capacity; VC, vital capacity; PFT, pulmonary
function testing; IVC, inspiratory vital capacity; SVC, slow vital capacity; ERV, expiratory reserve
volume; IRV inspiratory reserve volume; TV, tidal volume; TLC, total lung capacity; RV, residual
volume. Normal values are derived from [33].
Test Device/Method LLN Significance Recommendations
MEP Manometer Females 70 cm H2O,males 100 cm H2O
Expiratory muscle strength First-line, at least annually
PCF Peak flowmeter
270 L/min, airway clearance
impaired if 160–270 L/min,
airway clearance impossible
if <160 L/min
Reduced vital capacity
Reduced inspiratory and
expiratory muscle strength
First-line, at least annually
widely available
MIP Manometer Females 70 cm H2O,males 80 cm H2O
Inspiratory muscle strength First-line, at least annually
SNIP Manometer Females 60 cm H2O,males 70 cm H2O
Inspiratory muscle strength
Surrogate of MIP if
weakness of the orbicularis
oris muscle is present
VC Spirometry Upright > 80% of predicted VC,supine > 80% of upright VC
IRV + TV + ERV (global test of
lung volume and respiratory
muscle performance)
First-line, at least annually
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Testing should be carried out by trained staff at baseline (diagnosis) and at least once a year for
routine follow-up. Test intervals should be shorter (e.g., every 3–6 months) if signs and symptoms of
RMW are present or if acute exacerbation has just occurred. A nasal clip is obligatory except for SNIP
testing. Severe RMW is indicated by significant reduction of VC, ERV, or MIP/MEP/SNIP. TLC, RV,
and IC are not helpful for differentiation of severe and mild/moderate RMW.
3.5. Sleep Studies
Sleep-related symptoms should be assessed using standard questionnaires such as the Epworth
Sleepiness Scale [40], the Pittsburgh Sleep Quality Index [41], and the Fatigue Severity Scale [42]
since sleep disruption by nocturnal hypercapnia may contribute to physical exhaustion. However,
self-reported sleep outcomes do not specifically indicate SDB. Nocturnal hypercapnia can be detected
by nighttime blood gases or by the presence of an increased base excess (BE) during the day reflecting
compensatory retention of bicarbonate. A base excess >4 mmol/L has been shown to be a strong
predictor of nocturnal hypoventilation in patients with Duchenne muscular dystrophy [43]. If daytime
pCO2 and BE are normal, early morning blood gases may be more sensitive to unmask nocturnal
hypercapnia by showing either elevated or high-normal pCO2, or an increased BE. Normal daytime
blood gases do not exclude respiratory muscle weakness because compensatory tachypnea may
normalize or even decrease daytime pCO2. Pulse oximetry (PO) detects nocturnal oxygen desaturation.
Hypoventilation is indicated by peripheral oxygen saturation (SpO2) < 90% for five consecutive
minutes or more, a minimal SpO2 < 85%, or SpO2 < 90% for at least 30% of recording time. However,
PO may show normal results if hypoventilation is either mild or short-lasting. In these cases,
hypoventilation may be only unmasked by carbon dioxide (CO2) measurement. For this reason,
PO alone is not recommended as a screening tool for SDB in patients with NMD [44]. Combination of
PO and blood gas analysis may be considered clinically sufficient, practical and cost-effective if
more sophisticated sleep studies are not available or if patients cannot be seen in a specialized
center. Transcutaneous capnography allows non-invasive real-time monitoring of peripheral carbon
dioxide tension (tcCO2). It directly reflects alveolar ventilation and detects periods of nocturnal
hypoventilation (tcCO2 > 50 mmHg) with high sensitivity. Constant increase of tcCO2 during the
course of the night reflects decreased respiratory muscle endurance. Cardiorespiratory polygraphy
(PG) comprises registration of oxygen saturation, nasal and oral airflow, respiratory effort, heart
rate, and body position. It allows for identification of hypopneas, central and obstructive apneas,
nocturnal tachypnea, and prolonged episodes of hypoventilation reflected by persistent desaturation
in the absence of upper airway obstruction. PG should be preferred as a screening tool if concomitant
obstructive sleep apnea is suspected. Combination with blood gas analysis or capnography is strongly
recommended. Cardiorespiratory polysomnography (PSG) combines polygraphy, electrooculogram,
and electroencephalogram with optional videography. It allows for correlation of any respiratory event
with sleep and sleep stages. Combination of PSG and CO2 monitoring detects REM sleep-associated
hypercapnia as the earliest sign of nocturnal hypoventilation, thus yielding the highest sensitivity in
detecting SDB. Reduced REM sleep is a frequent finding in patients with significant respiratory muscle
weakness [29]. Full PSG is generally recommended for baseline evaluation of sleep (Figure 1) [44].
3.6. Daytime Blood Gas Analysis
Daytime blood gases do not necessarily have to be drawn from arterial blood since this procedure
may often be restricted to specialized respiratory units or laboratories, respectively. Blood gases taken
from the arterialized earlobe or serum bicarbonate from a routine electrolyte panel are sufficient and
more readily available. Serum bicarbonate does reflect chronic alveolar hypoventilation in NMD and
other hypoventilation syndromes [45].
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4. Management
4.1. Mechanical Ventilation
Mechanical ventilation has improved survival in NMD with progressive respiratory
involvement [46]. It comprises non-invasive ventilation (NIV) and tracheostomy invasive ventilation
(TIV). NIV has been shown to effectively correct alveolar hypoventilation and alleviate sleep-related
Int. J. Mol. Sci. 2016, 17, 1735 7 of 17
symptoms in patients with both infantile-onset and juvenile/adult onset Pompe disease [47–49].
Mechanical ventilation corrects nocturnal hypercapnia and re-sensitizes respiratory centers to CO2
by persistently decreasing plasma bicarbonate levels [50]. Intermittent mechanical ventilation may
influence strength and endurance of respiratory muscles. In addition, it promotes rib cage and
lung expansion which may help prevent atelectasis, ventilation-perfusion mismatch, and infections.
Ventilator-induced diaphragmatic dysfunction due to long-term ventilation has been described in
critically ill patients [51] but has not been investigated in patients with NMD receiving intermittent
ventilatory support.
4.1.1. Non-Invasive Ventilation (NIV)
Indication criteria for NIV in chronic respiratory failure due to NMD can be adopted from existing
guidelines (Table 2) [32]. Conditions promoting or worsening respiratory failure should be ruled out
or treated adequately. Ventilation mode, ventilator settings, and interfaces should be personalized
by experienced personnel according to sleep study results and individual needs. In a few cases sleep
studies may be expendable if daytime hypercapnia or very severe respiratory muscle weakness is
present, but the presence of concomitant obstructive sleep apnea should not be missed regarding its
relevance for pressure settings. Humidification should always be offered. Nasal masks may be more
comfortable, but oronasal interfaces reduce air leakage, and even mouthpieces have successfully been
used in patients with NMD on long-term NIV. Titration of ventilator settings and treatment evaluation
should be performed using PSG and CO2 monitoring. For routine follow-up, serum bicarbonate on
both NIV and spontaneous breathing may be sufficient if NIV is used regularly and patient comfort
is good [52]. Blood gas analysis and sleep studies including capnometry are necessary if serum
bicarbonate is elevated or in case of patient discomfort, recurring symptoms of SDB, or marked
progression of respiratory muscle weakness.
Table 2. General indications and contraindications for the initiation of long-term positive pressure
ventilation in patients with neuromuscular disease [26]. FVC, forced vital capacity; MIP, maximal
inspiratory pressure; SDB, sleep-disordered breathing; paCO2, partial pressure of carbon dioxide;
RMW, respiratory muscle weakness; saO2, oxygen saturation; tcCO2, transcutaneous carbon dioxide
tension; TIV, tracheostomy invasive ventilation.
Mode Non-Invasive Ventilation (NIV) Invasive Ventilation (IV/TIV)
Indications
• Symptoms of SDB or significant inspiratory muscle weakness • Failure of NIV
• Persistent NIV intolerance
• Contraindications to NIV
• NIV > 20 h/day (consider)
• Acute
respiratory compromise
and at least one of the following:
• Daytime hypercapnia (paCO2 ≥45 mmHg)
• Nocturnal hypercapnia (paCO2/tcCO2 > 50 mmHg)
• Nocturnal oxygen desaturation (SaO2) < 90% for at least five
Consecutive minutes
• Overnight increase of pCO2/tcCO2 > 10 mmHg from baseline
• FVC < 50% predicted
• MIP < 60 cm H2O (if rapid deterioration of RMW is present)
Contraindications
Relative • Inadequate caregiver support• Severe dysphagia
• Inadequate caregiver support
• Initial need for full-time ventilation
Absolute
• Persistent upper airway obstruction
• Persistent hypersecretion
• Inability to co-operate
• Inefficient cough (even with assistance)
4.1.2. Tracheostomy Invasive Ventilation (TIV)
Indications and contraindications for invasive ventilation are depicted in Table 2. In case of NIV
failure one should address inadequate ventilator settings, mucus obstruction, or mask intolerance
before tracheostomy is considered. For patients with advanced disease and tetraplegia or with serious
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comorbidities, it may be appropriate to offer palliative care instead of TIV, especially if ceiling of care
is part of an advanced directive. Long-term TIV should be administered by an experienced center with
trained home support technicians. Surgical tracheostomy should be preferred. Continous mandatory
ventilation is obligatory including humidification, and uncuffed or deflated tracheostomy tubes should
be used to support speech and swallowing. Patients should be equipped with two ventilators and
adequate devices necessary for oxymetry, assisted cough, and suction. Caregivers should receive
both comprehensive training and 24/7 online technical support. Follow-up of patients receiving TIV
includes blood gas analysis under ventilation and spontaneous breathing (if possible), oxymetry, and
nocturnal CO2 monitoring, if appropriate. In-hospital evaluation including PFT, blood gas analysis,
and sleep studies is recommended in case of patient discomfort, symptoms suggestive of persistent
hypercapnia, or acute respiratory failure. For patients on long-term NIV or TIV, a second ventilator
should be provided if mechanical ventilation exceeds 16 h a day, and a battery-powered device should
be prescribed in order to maintain mobility (e.g., by attaching it to a wheelchair), and for safety reasons
in case of power cuts.
4.2. Respiratory Muscle Training
Respiratory muscle training (RMT) includes strength and endurance training, and has been
shown to improve respiratory muscle function in healthy adults, patients with cervical spinal
cord injury, and patients with muscular dystrophy [53–55]. Several small studies have shown that
respiratory muscle strength training (RMST) is feasible and improves respiratory muscle strength
in patients with adult Pompe disease and children who survived infantile Pompe disease on
ERT [56–59]. However, evidence is still scarce, and effects of RMT have not yet been investigated
using non-volitional measures of respiratory muscle function. As a preliminary recommendation
RMST may be carried out on a long-term daily basis using handheld pressure-threshold training
devices set to provide a pressure-threshold of 60%–70% of individual MIP and MEP. MIP and MEP
should be regularly re-measured and pressure settings adjusted according to treatment success.
RMST is not recommended for patients with perforated tympanic membranes, oro-facial weakness,
established daytime hypercapnia or thoracic instability. Endurance training as part of RMT has
not been investigated in patients with Pompe disease, but preliminary data on other NMD suggest
beneficial effects [60,61].
4.3. Cough Assistance
As acute respiratory failure (ARF) is a major cause of morbidity and mortality in adult Pompe
disease, the management of decreased airway clearance capacity is of utmost importance if expiratory
muscle weakness is present. Chest physiotherapy and manually-assisted cough (MAC) may be
sufficient only for patients with mild exspiratory muscle weakness. Standard maneuvers include
postural drainage and manual techniques (e.g., abdominal thrust maneuvers, thoracic percussion, and
special breathing gymnastics). MAC techniques should be implemented by trained physiotherapists
or respiratory therapists. MAC efficacy can be improved by voluntary deep breathing or additional
techniques which increase expiratory airflow including hyperinflation or air stacking by means
of a manual insufflator like a bag valve mask [62] or by glossopharyngeal (“frog”) breathing [63].
In ventilated patients, air stacking can be achieved by applying several mandatory breaths in
the volumetric mode while expiration is blocked. Air stacking combined with MAC is generally
recommended if cough assistance is indicated and upper airways are patent in cooperative patients [64].
Insufflation/Exsufflation (I/E) devices offer additional cough support by combining full inflation of
the lungs and rapid delivery of negative airway pressure, which results in a high peak expiratory
flow. I/E devices can be applied either using a face mask or on a tracheostomy tube. They have been
shown to improve PCF and airway clearance resulting in significant risk reduction with regard to
ARF and hospitalization [65]. High frequency chest wall oscillation (HFCWO) and intrapulmonary
percussive ventilation (IPV) promote mucociliary clearance and may help to propel secretions forward
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from the periphery to the central airways. HFCWO uses an inflatable jacket or cuirass to generate
oscillations of the chest wall (5–20 Hz). IPV involves superimposed high frequency mini pressure
bursts applied via a nasal-oral mask to create intrapulmonary vibrations. The superiority of either
technique has not been demonstrated in NMD [66,67]. Practical recommendations on cough assistance
are summarized in Table 3. Contraindications for I/E devices, HFCWO, and IPV include emphysema,
chest wall instability, uncontrolled asthma or heart failure, pneumothorax, and pneumomediastinum.
Table 3. Practical recommendations for cough assistance in patients with LOPD. MAC, manually
assisted coughing; I/E, insufflation/exsufflation; HFCWO, high frequency chest wall oscillation; NIV,
non-invasive ventilation; TIV, tracheostomy invasive ventilation; PCF, peak cough flow; MEP, maximal
expiratory pressure.
Symptoms Mucus obstruction, recurrent desaturations, recurrent pulmonary infections
Testing PCF, MEP
When to start
• PCF < 270 L/min once during stable state independent of symptoms
• PCF < 160 L/min once during acute exacerbation
• MEP < 60 cm H2O with history of impaired airway clearance
Techniques
MAC
• If patient is willing and able to co-operate
• Performed by respiratory therapists or trained caregivers
• Re-evaluate feasibility and effectiveness
• Switch to mechanical techniques if MAC is not feasible or proves ineffective
Air
stacking
• Usually in combination with MAC
• Via bag valve mask in the non-invasive setting
• Via ventilator device (with NIV or TIV, respectively)
I/E
• If MAC/air stacking are not feasible or ineffective
• May be combined with MAC
• Individually titrate optimal pressure settings
• Feasible in both the NIV and TIV setting
• Re-evaluate using PCF as outcome measure
• Start early in case of pulmonary infection
HFCWO
• If MAC/air stacking are either not feasible or ineffective
• If I/E cannot be tolerated
• May be combined with MAC
• Individually titrate frequency and duration
• Feasible in both the NIV and TIV setting
• May be combined with suction
• Start early in case of pulmonary infection
Optional measures Mucolysis Hydration, mucolytics (with caution)
Suction If expectoration cannot be achieved by MAC, I/E, HFCWO alone
4.4. Management of Acute Respiratory Failure
Any condition leading to acute respiratory failure (ARF) in a patient with LOPD is potentially
life-threatening. There is a risk of dramatic physical and mental deterioration if ARF is handled without
taking Pompe disease into account. Patients are at risk of death or loss of motor abilities that can never
be regained. ARF may result from infection, post-surgery complication, or insidious onset progress of
respiratory muscle weakness. In addition, acute worsening of hypercapnia may be caused by either
the use of respiratory depressants and diuretics, or by oxygen supplementation when NIV has not
been established at the same time. Ideally, a multidisciplinary team familiar with both Pompe disease
in general and the individual patient in particular will have planned in advance how to avoid ARF
and how to manage ARF if it occurs. If possible, elective surgery should be performed at specialized
centers in order to avoid secondary transportation. Practical recommendations for management of
ARF in adult Pompe disease patients are summarized in Table 4.
Int. J. Mol. Sci. 2016, 17, 1735 10 of 17
Table 4. Management of acute respiratory failure (ARF) in patients with LOPD. ERT, enzyme replacement
therapy; ICU, intensive care unit; RICU, respiratory intermediate care unit; NIV, non-invasive ventilation;
TIV, tracheostomy invasive ventilation; I/E, insufflation/exsufflation; HFCWO, high frequency chest
wall oscillation.
• Admission to ICU or RICU [68]
• Broad spectrum antibiotics
• Avoid opiates and paralytics
• Always prefer NIV to TIV if possible
• If TIV is inevitable, aim for early closure of tracheostomy and re-start of NIV
• Aggressively treat airway secretions (I/E, HFCWO, bronchoscopy)
• Start respiratory rehabilitation as early as possible
• Evaluate patients without ventilatory support prior to ARF for NIV indication
• After rehabilitation, reinforce long-term prophylactic measures (e.g., cough assistance, immunizations)
• ERT not to be paused
4.5. Additional Recommendations
4.5.1. Immunizations
Preventing respiratory infections in patients with Pompe disease is clinically important and
vaccines play a crucial preventive role. It is recommended that patients with Pompe disease,
whether or not they are receiving ERT, receive the same vaccinations as subjects of similar age and
comorbidity [69]. Annual influenza vaccination is recommended after emergence of clinically relevant
respiratory muscle impairment. Pneumococcal vaccination should be considered mandatory according
to standard recommendations.
4.5.2. Obstructive Sleep Apnea
Macroglossia and pharyngeal narrowness are risk factors for obstructive sleep apnea (OSA) [70].
Hypertrophy and weakness of the tongue have been described in adult Pompe disease [71,72] and OSA
has been reported in 3 out of 27 patients [28]. Continuous positive airway pressure (CPAP) is the gold
standard for treatment, but since it may cause increased diaphragmatic strain, it should be considered
only in patients with isolated OSA without signs or symptoms of respiratory muscle weakness.
Regular follow-up sleep studies are recommended, and NIV should be started once respiratory muscle
weakness is detected.
4.5.3. Concomitant Pulmonary Disease
Concomitant pulmonary disease should be treated according to disease-specific guidelines.
Patients with chronic obstructive pulmonary disease (COPD) are at high risk of developing early
type 2 respiratory failure since respiratory muscle weakness may be significantly enhanced by
chronic hypoxemia, high ventilatory rate, and increased dead space ventilation. Excessive oxygen
supplementation may lead to both decreased respiratory drive and worsening of ventilation-perfusion
mismatch further promoting hypercapnia. In patients with mild respiratory muscle weakness, REM
sleep-associated hypoventilation is much more likely to occur if COPD is present. In summary, in
patients with Pompe disease and lung disease we recommend more frequent sleep studies and early
initiation of NIV, if indicated. Long-term oxygen treatment should not be implemented without
thorough evaluation of respiratory muscle function and nocturnal ventilation, and it is advisable to
simultaneously start NIV.
4.5.4. Perioperative Management
Recommendations can only be deduced from single case reports, general considerations on
anesthesia in NMD, and own experience. Local anesthesia is generally preferred. If general anesthesia
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is required, patients should be referred to centers experienced in the perioperative care of patients
with NMD. Whereas propofol may be disadvantageous in patients with infantile-onset Pompe disease
and cardiomyopathy [73], there is no evidence that it should not be used in patients with LOPD.
Both ketamine and etomidate can be safely used for induction of general anesthesia [74]. Patients are
more sensitive to neuromuscular blockade, and prolonged weaning should always be anticipated.
The perioperative use of opioids may add to this risk by depressing respiratory drive and increasing
chest wall rigidity. If scoliosis is present, epidural or spinal anesthesia may be difficult to perform and
require special expertise and precautions [75].
4.5.5. Scoliosis
Scoliosis has been reported in one-third of patients with all types of Pompe disease [76] and in
16% of patients with LOPD [77]. Severe scoliosis may impair ventilation increasing the risk of SDB
and daytime hypercapnia. Orthopedic management should aim to reduce pain, sitting instability,
and lung restriction. Patients should be referred to specialized spine centers. Spinal surgery may
be advisable in some patients [78]. Non-surgical treatment includes individualized corsets and
long-term physiotherapy.
4.5.6. Nutrition
Patients with adult Pompe disease, particularly with juvenile disease onset, are prone to underweight
or even cachexia which may add to respiratory muscle dysfunction [79]. Nutritional counseling should
focus on improving BMI, abdominal circumference, body fat content, and hip-waist-ratio. Rarely,
percutaneous endoscopic gastrostomy may be considered in patients with advanced disease or severe
bulbar dysfunction, respectively.
4.5.7. Chronic Pain
In patients with adult Pompe disease and chronic pain requiring long-term analgesia with opioids,
respiratory drive and chest wall compliance may be reduced. Long-term opioid use directly affects
sleep architecture and sleep-related breathing [80] making more frequent sleep studies advisable.
4.5.8. Palliative Care
Initiation of palliative care should be considered in patients who have continuous NIV or invasive
ventilation without durable improvement or any concomitant fatal disease. There are no specific
guidelines for palliative care for patients with Pompe disease or proximal myopathies in general.
However, general recommendations can be adopted from guidelines referring to other types of NMD
associated with chronic respiratory failure.
4.5.9. Patient and Caregiver Education
Patient and caregiver education with regard to respiratory issues is crucial for recognition and
early treatment of any problem related to RMW in patients with Pompe disease. In particular,
patients and caregivers should be regularly informed about potential complications, vaccination
issues, prevention of ARF, and the importance of sleep-related symptoms as indicators of RMW.
5. Methods
The Pompe Respiratory Care Working Group initially met at the 2012 European symposium
“Steps Forward in Pompe Disease” (Berlin, Germany) to establish the need for up-to-date expert
recommendations on respiratory management of adult patients with Pompe disease. The group began
work in 2013 and convened for a two-day meeting in March 2014. Discussions were centered around
defining the optimal tests and treatments for respiratory function in terms of clinical validity and
relevance, accessibility, cost-effectiveness, and reliability. In addition, for each clinical problem or
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paraclinical test, any disease-specific evidence available was evaluated. If no evidence with special
regard to Pompe disease was obtainable, expert recommendations and clinical guidelines focusing on
other NMD, or NMD in general, were consulted. All working group members reviewed and approved
the draft and final recommendations.
6. Conclusions
Respiratory muscle involvement is a prominent feature of Pompe disease, substantially affecting
quality of life, morbidity, and mortality. Thus, adult Pompe disease can be considered a “model
disease” for myopathies of adult age, which require close and life-long interdisciplinary co-operation
between neurologists and pulmonologists once diagnosis has been established. Although recent
pharmacotherapeutic approaches have opened promising perspectives for patients with Pompe disease,
respiratory muscle weakness will always affect a large number of patients. Optimal care includes
thorough follow-up of respiratory muscle function and sleep-related breathing. Treatment options aim
to either delay or compensate for significant respiratory muscle weakness in order to improve overall
quality of life and avoid life-threatening complications. Thus, early initiation of adequate treatment is
essential, and it is strongly recommended to link patients to specialized centers.
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ARF Acute respiratory failure
BE Base excess
BIPAP Bilevel inspiratory positive airway pressure
CO2 Carbon dioxide
COPD Chronic obstructive pulmonary disease
CPAP Continuous positive airway pressure
ERT Enzyme replacement therapy
ERV Expiratory reserve volume
FVC Forced vital capacity
GAA α-1,4-glucosidase
HFCWO High frequency chest wall oscillation
IC Inspiratory capacity
ICU Intensive care unit
I/E Insufflation/exsufflation
IPV Intrapulmonary percussive ventilation
IRV Inspiratory reserve volume
IVC Inspiratory vital capacity
LOPD Late-onset Pompe disease
MAC Manually assisted coughing
MEP Maximum expiratory pressure
MIP Maximum inspiratory pressure
NIV Non-invasive ventilation
NMD Neuromuscular disorders
OSA Obstructive sleep apnea
PCF Peak cough flow
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pCO2 Carbon dioxide tension
PFT Pulmonary function testing
Pdi Twitch diaphragmatic pressure
Pmo Twitch mouth pressure
PO Pulse oximetry
PSG Polysomnography
REM Rapid eye movement
RICU Respiratory intermediate care unit
RMW Respiratory muscle weakness
RMST Respiratory muscle strength training
RMT Respiratory muscle training
RV Residual volume
SaO2 Arterial oxygen saturation
SDB Sleep-disordered breathing
SNIP Sniff nasal inspiratory pressure
SpO2 Peripheral oxygen saturation
SVC Slow vital capacity
tcCO2 Transcutaneous carbon dioxide tension
TLC Total lung capacity
TV Tidal volume
VC Vital capacity
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